• Je něco špatně v tomto záznamu ?

Antiandrogenní terapie a ozařování v porovnání se samotným ozařováním při léčbě karcinomu prostaty. Randomizovaná klinická studie
[Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial]

Anthony V. D'Amico, Ming-Hui Chen, Andrew A. Renshaw, Marian Loffredo, Philip W. Kantoff ; přeložil Aleš Chrdle

. 2008 ; 16 (4) : 178-185.

Jazyk čeština Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc07514481

Comorbidities may increase the negative effects of specific anticancer treatments such as androgen suppression therapy (AST). OBJECTIVES: To compare 6 months of AST and radiation therapy (RT) to RT alone and to assess the interaction between level of comorbidity and all-cause mortality. DESIGN, SETTING, AND PATIENTS: At academic and community-based medical centers in Massachusetts, between December 1, 1995, and April 15, 2001, 206 men with localized but unfavorable-risk prostate cancer were randomized to receive RT alone or RT and AST combined. All-cause mortality estimates stratified by randomized treatment group and further stratified in a postrandomization analysis by the Adult Comorbidity Evaluation 27 comorbidity score were compared using a log-rank test. MAIN OUTCOME MEASURE: Time to all-cause mortality. RESULTS: As of January 15, 2007, with a median follow-up of 7.6 (range, 0.5-11.0) years, 74 deaths have occurred. A significant increase in the risk of all-cause mortality (44 vs 30 deaths; hazard ratio [HR], 1.8; 95% confidence interval [CI], 1.1-2.9; P = .01) was observed in men randomized to RT compared with RT and AST. However, the increased risk in all-cause mortality appeared to apply only to men randomized to RT with no or minimal comorbidity (31 vs 11 deaths; HR, 4.2; 95% CI, 2.1-8.5; P < .001). Among men with moderate or severe comorbidity, those randomized to RT alone vs RT and AST did not have an increased risk of all-cause mortality (13 vs 19 deaths; HR, 0.54; 95% CI, 0.27-1.10; P = .08). CONCLUSIONS: The addition of 6 months of AST to RT resulted in increased overall survival in men with localized but unfavorable-risk prostate cancer. This result may pertain only to men without moderate or severe comorbidity, but this requires further assessment in a clinical trial specifically designed to assess this interaction. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00116220.

Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial

Bibliografie atd.

Lit.: 28

000      
00000naa 2200000 a 4500
001      
bmc07514481
003      
CZ-PrNML
005      
20111210124917.0
008      
081230s2008 xr e cze||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a D'Amico, Anthony V.
245    10
$a Antiandrogenní terapie a ozařování v porovnání se samotným ozařováním při léčbě karcinomu prostaty. Randomizovaná klinická studie / $c Anthony V. D'Amico, Ming-Hui Chen, Andrew A. Renshaw, Marian Loffredo, Philip W. Kantoff ; přeložil Aleš Chrdle
246    11
$a Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial
314    __
$a Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston
504    __
$a Lit.: 28
520    9_
$a Comorbidities may increase the negative effects of specific anticancer treatments such as androgen suppression therapy (AST). OBJECTIVES: To compare 6 months of AST and radiation therapy (RT) to RT alone and to assess the interaction between level of comorbidity and all-cause mortality. DESIGN, SETTING, AND PATIENTS: At academic and community-based medical centers in Massachusetts, between December 1, 1995, and April 15, 2001, 206 men with localized but unfavorable-risk prostate cancer were randomized to receive RT alone or RT and AST combined. All-cause mortality estimates stratified by randomized treatment group and further stratified in a postrandomization analysis by the Adult Comorbidity Evaluation 27 comorbidity score were compared using a log-rank test. MAIN OUTCOME MEASURE: Time to all-cause mortality. RESULTS: As of January 15, 2007, with a median follow-up of 7.6 (range, 0.5-11.0) years, 74 deaths have occurred. A significant increase in the risk of all-cause mortality (44 vs 30 deaths; hazard ratio [HR], 1.8; 95% confidence interval [CI], 1.1-2.9; P = .01) was observed in men randomized to RT compared with RT and AST. However, the increased risk in all-cause mortality appeared to apply only to men randomized to RT with no or minimal comorbidity (31 vs 11 deaths; HR, 4.2; 95% CI, 2.1-8.5; P < .001). Among men with moderate or severe comorbidity, those randomized to RT alone vs RT and AST did not have an increased risk of all-cause mortality (13 vs 19 deaths; HR, 0.54; 95% CI, 0.27-1.10; P = .08). CONCLUSIONS: The addition of 6 months of AST to RT resulted in increased overall survival in men with localized but unfavorable-risk prostate cancer. This result may pertain only to men without moderate or severe comorbidity, but this requires further assessment in a clinical trial specifically designed to assess this interaction. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00116220.
650    _2
$a adenokarcinom $x farmakoterapie $x radioterapie $7 D000230
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antagonisté androgenů $x terapeutické užití $7 D000726
650    _2
$a hormonální protinádorové látky $x terapeutické užití $7 D018931
650    _2
$a příčina smrti $7 D002423
650    _2
$a adjuvantní chemoterapie $7 D017024
650    _2
$a komorbidita $7 D015897
650    _2
$a flutamid $x terapeutické užití $7 D005485
650    _2
$a následné studie $7 D005500
650    _2
$a hormon uvolňující gonadotropiny $x agonisté $7 D007987
650    _2
$a lidé $7 D006801
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádory prostaty $x farmakoterapie $x mortalita $x radioterapie $7 D011471
650    _2
$a konformní radioterapie $7 D020266
700    1_
$a Chen, Ming-Hui
700    1_
$a Renshaw, Andrew A.
700    1_
$a Loffredo, Marian
700    1_
$a Kantoff, Philip W.
700    1_
$a Chrdle, Aleš. $7 xx0253541
773    0_
$w MED00011025 $t JAMA $g Roč. 16, č. 4 (2008), s. 178-185 $x 1210-4132
910    __
$a ABA008 $b B 1805 $c 1156 $y 9
990    __
$a 20081229160959 $b ABA008
991    __
$a 20081230115346 $b ABA008
999    __
$a ok $b bmc $g 630078 $s 482533
BAS    __
$a 3
BMC    __
$a 2008 $b 16 $c 4 $d 178-185 $i 1210-4132 $m JAMA (České a slovenské vyd.) $x MED00011025
LZP    __
$a 2008-24/mkme

Najít záznam

Citační ukazatele

Možnosti archivace